A photo of Nadim Khalil.

Clinical Fellow, Division of Infectious Diseases


About Me


My primary research area is studying predisposing components and results linked with resistant gram-negative invasive infections. I’m investigating the risks that lead patients to have a higher chance of becoming infected due to a resistant pathogen.

I am very interested in pinpointing the risk factors that pose a greater likelihood of patients acquiring an infection from a resistant pathogen. Figuring out this information would be quite useful for providers treating patients at risk of aggressive infections by lowering the incidence of resistant pathogens.

I recognized my passion for infectious disease research during my medical school training. I worked with many patients with multi-drug resistant bacteria, including Vancomycin-resistant enterococci, multi-drug-resistant tuberculosis and Carbapenem-resistant Enterobacteriaceae. The exposure to these patients elevated my awareness of the rising rate of resistant bacteria around the world and the dangers they pose.

When I was in high school and college, I volunteered at a children’s cancer facility. Back then, I interacted with children who had a higher risk of infection. This experience led me to pursue a career in the medical field and, in particular, pediatrics healthcare. Ultimately, I settled on a specialty in pediatric infectious diseases.

During my career, I received the Helen’s Grant Fund (2017) from the Dartmouth-Hitchcock Medical Center. This award funded my research on the early onset neonatal sepsis systematic review.

My research has been published in the journal Diagnostic Microbiology and Infectious Disease. Lastly, I am fluent in English, French and Arabic. I’m learning Spanish and hope to become fluent soon.

Clinical Interests

Pediatric infectious diseases

Research Interests

Gram negative bacteremia; increasing global rates of antimicrobial resistance

Clinical Divisions

Infectious Diseases

My Education

MD: American University of Beirut, Lebanon, 2014.

Internship: American University of Beirut Medical Center, Lebanon, 2014-2015.

Residency: Pediatrics: Children's Hospital at Dartmouth, Hanover, NH.

My Publications

Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; et al. Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review. Peck, GM; Staat, MA; Huang, FS; Khalil, N; Boyce, C; Kohlrieser, CM; Schlaudecker, EP. Pediatric Pulmonology. 2021.

Combined Molecular and Phenotypic Antimicrobial Susceptibility Testing Is Beneficial in Detection of ESBL and AmpC Beta-Lactamase Producing Isolates of Enterobacteriaceae in Pediatric Patients with Bloodstream Infections. Powell, EA; Khalil, N; Deburger, B; Mortensen, JE. Microbial Drug Resistance. 2020; 26:825-830.

Neonatal early onset sepsis in Middle Eastern countries: a systematic review. Khalil, N; Blunt, HB; Li, Z; Hartman, T. Archives of Disease in Childhood. 2020; 105:639-647.

Neonatal bacteremia and oligoarthritis caused by Rhodococcus corynebacterioides/Rhodococcus kroppenstedtii. Khalil, N; Corker, L; Powell, EA; Mortensen, JE. Diagnostic Microbiology and Infectious Disease. 2019; 94:395-397.